Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563106 · ClinicalTrials.gov registry record · Phase 2
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
A Phase 2 study, sponsored by Theriva Biologics.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT02563106 is a Phase 2 study that has completed, run by Theriva Biologics. The registered enrollment target is 413 participants.
The verdict
NCT02563106, a Phase 2 study, has completed, sponsored by Theriva Biologics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract Infection (LRTI).
Interventions
- DRUG Placebo
- DRUG SYN-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02563106
The ClinicalTrials.gov registry entry for NCT02563106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theriva Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02563106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02563106 about?
NCT02563106 is a clinical study titled "A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI". A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract Infection (LRTI).
What is the current status of trial NCT02563106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2015-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02563106?
The interventions under investigation include: Placebo (DRUG), SYN-004 (DRUG).
Who is sponsoring clinical trial NCT02563106?
This trial is sponsored by Theriva Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.